Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development

   Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical

PR Newswire

LA JOLLA, Calif., Nov. 27, 2012

LA JOLLA, Calif., Nov. 27, 2012 /PRNewswire/ -- Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today the
appointment of Victor Knopov, Ph.D. to its executive management team as Vice
President, Pharmaceutical Development. Dr. Knopov joined Regulus from Nitto
Denko Technical Corporation where he served as Director, Chemistry
Manufacturing Control  since 2010.

"Victor is a recognized expert in oligonucleotide drug delivery with over
thirty years of experience," said Neil W. Gibson, Ph.D., Regulus' Chief
Scientific Officer. "He will strengthen our accomplished management team and
provide pharmaceutical development expertise as we advance our microRNA
therapeutic programs toward the clinic."

"Regulus' mature product platform and established leadership in the microRNA
field make joining the team an exciting opportunity for me," said Dr. Knopov.
"I look forward to driving our microRNA therapeutic programs into clinical

Dr. Knopov has extensive knowledge of Chemistry, Manufacturing and Control, or
CMC, development for various technology platforms including commercial
production of enzymes, small anticancer liposomal products as well as advanced
delivery systems for antisense, plasmids and siRNA based on lipids, polymer
nanoparticles and conjugated systems. Prior to joining Nitto Denko Technical
Corporation, from 2008 to 2010, Dr. Knopov was Chief Operating Officer at
Diversified Bio-Medics, Inc. and an executive management consultant for CMC
development at EnGene, Inc. and Marina Biotech, Inc. From 1997 to 2008, Dr.
Knopov held various pharmaceutical manufacturing positions at Inex
Pharmaceuticals Corporation where he led development for several
pharmaceutical and biotech companies.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting microRNAs.
Regulus is leveraging a mature therapeutic platform based on technology that
has been developed over 20 years. Regulus works with a broad network of
academic collaborators and leverages the oligonucleotide drug discovery and
development expertise of its founding companies, Alnylam Pharmaceuticals
(NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus is advancing
microRNA therapeutics toward clinical development in several areas, including
oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed
strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a
research collaboration with Biogen Idec.

For more information, please visit

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., +1-858-202-6300,; David Schull, Russo Partners LLC, Media Contact,
Press spacebar to pause and continue. Press esc to stop.